Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | LPO | P22079 | 1/20 | 0.44 |
| ▸ | LDHA | P00338 | 4/20 | 0.39 |
| ▸ | LDHB | P07195 | 4/20 | 0.39 |
| ▸ | FDPS | P14324 | 2/20 | 0.39 |
| ▸ | CCR9 | P51686 | 1/20 | 0.39 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL7373319 | 0.98 | RAB9A (0.48) | TSHRRAB9ASMN1; SMN2NAMPTHTT | |
| SCHEMBL12234495 | 0.84 | — | — | |
| SCHEMBL405925 | 0.84 | — | — | |
| SCHEMBL114011 | 0.84 | — | — | |
| Trifluoromethanesulfonic Acid SCHEMBL9016873 | 0.84 | SMN1; SMN2 (0.46) | TSHRRAB9ASMN1; SMN2NAMPTHTT | |
| SCHEMBL1045991 | 0.82 | SMN1; SMN2 (0.58) | TSHRRAB9ASMN1; SMN2NAMPTHTT | |
| SCHEMBL711909 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL16239625 | 0.82 | NAMPT (0.45) | TSHRRAB9ASMN1; SMN2NAMPTHTT | |
| SCHEMBL284637 | 0.82 | — | — | |
| Water SCHEMBL29957253 | 0.82 | NAMPT (0.45) | TSHRRAB9ASMN1; SMN2NAMPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019142208-A1 | AMBIENT TEMPERATURE CURABLE NON-ISOCYANATE POLYHYDROXYALKYLURETHANE MOIETIES WITH ALDEHYDE CROSS LINKER | Asian Paints Ltd. (IN) | 2019-07-25 | — | — | WO | claimed |
| WO-2025132825-A1 | 1H-IMIDAZO[4,5-C]QUINOLINE METAL-BASED COMPLEXES USEFUL AS MEDICAMENTS | FUNDACIÓN DONOSTIA INTERNATIONAL PHYSICS CENTER - DIPC (ES) | 2025-06-26 | — | — | WO | disclosed |
| US-20250111889-A1 | DE NOVO DESIGNED MACROCYCLIC OLIGOAMIDES | UNIVERSITY OF WASHINGTON | 2025-04-03 | — | — | US | disclosed |
| WO-2019142208-A1 | AMBIENT TEMPERATURE CURABLE NON-ISOCYANATE POLYHYDROXYALKYLURETHANE MOIETIES WITH ALDEHYDE CROSS LINKER | Asian Paints Ltd. (IN) | 2019-07-25 | — | — | WO | disclosed |
| EP-1390340-B1 | COPPER-CATALYZED FORMATION OF CARBON-HETEROATOM AND CARBON-CARBON BONDS | MASSACHUSETTS INST TECHNOLOGY (US) | 2017-03-01 | — | — | EP | disclosed |
| US-9067955-B2 | Copper-catalyzed formation of carbon-heteroatom and carbon—carbon bonds | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-06-30 | — | — | US | disclosed |
| EP-1390340-A4 | COPPER-CATALYZED FORMATION OF CARBON-HETEROATOM AND CARBON-CARBON BONDS | MASSACHUSETTS INST TECHNOLOGY (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20060264673-A1 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2006-11-23 | — | — | US | disclosed |
| CN-1854128-A | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | MASSACHUSETTS INST TECHNOLOGY (US) | 2006-11-01 | — | — | CN | disclosed |
| US-7115784-B2 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2006-10-03 | — | — | US | disclosed |
| US-5705703-A | ENZYME INHIBITORS OF TRANSFERASES | HOFFMANN-LA ROCHE INC. (US) | 1998-01-06 | — | — | US | disclosed |
| US-5633371-A | ENZYME INHIBITORS; TREATMENT OF DEPRESSION AND PARKINSON*S DISEASE | HOFFMANN-LA ROCHE INC. (US) | 1997-05-27 | — | — | US | disclosed |
| US-5389653-A | Inhibitors of the enzyme catechol-O-methyltransferase; useful as co-medication in treatment of Parkinson's disease | HOFFMAN-LA ROCHE INC. (US) | 1995-02-14 | — | — | US | disclosed |
| EP-0623130-A1 | ANTIBACTERIAL 1-NORMON-2-YL THIAZOLYL KETONES | SMITHKLINE BEECHAM PLC (GB) | 1994-11-09 | — | — | EP | disclosed |
| US-5236952-A | Inhibit the enzyme catechol-O-methyltransferase; for treatment of Parkinson's disease administered with L-dopa | HOFFMANN-LA ROCHE INC. (US) | 1993-08-17 | — | — | US | disclosed |
| WO-1993015072-A1 | ANTIBACTERIAL 1-NORMON-2-YL THIAZOLYL KETONES | SMITHKLINE BEECHAM PLC (GB) | 1993-08-05 | — | — | WO | disclosed |
| EP-0544705-A1 | DERIVATIVES OF MUPIROCIN | Beecham Group p.l.c. (GB) | 1993-06-09 | — | — | EP | disclosed |
| EP-0237929-B1 | 3,5-DISUBSTITUTED PYROCATECHOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1993-06-02 | — | — | EP | disclosed |
| WO-1992002518-A1 | DERIVATIVES OF MUPIROCIN | BEECHAM GROUP PLC (GB) | 1992-02-20 | — | — | WO | disclosed |
| EP-0237929-A1 | 3,5-Disubstituted pyrocatechol derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1987-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264673-A1 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | ADH5, CBR3, ALDH3A1 | TSHR 3079/4885RAB9A 3411/4885SMN1; SMN2 3768/4885 |
| US-20250111889-A1 | DE NOVO DESIGNED MACROCYCLIC OLIGOAMIDES | DHFR, CCNH, ODC1 | TSHR 1979/4885RAB9A 4418/4885SMN1; SMN2 1509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.